

C-CAMP-GARDP collaborate to tackle global health threat of antimicrobial resistance

26 December 2022 | News

With emphasis on solutions that are also deployable in low- and middle- income countries

Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has joined forces with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the global problem of resistant bacterial infections.

Both parties have a joint aspiration to assist in fast-tracking the clinical development, validation and integration of innovative diagnostic solutions for antimicrobial resistance (AMR) into the health system for access by end-users including clinicians, laboratories, and hospitals.

The letter of intent was signed recently by Dr Taslimarif Saiyed, CEO-Director of C-CAMP, Dr François Franceschi, Head of Asset Evaluation and Development at GARDP, and Dr Subasree Srinivasan, GARDP Medical Director.

This letter of intent underlines C-CAMP's growing prominence as a global destination for cutting-edge AMR innovations. Dr Saiyed said, "This collaboration would allow C-CAMP to leverage its significant network in the Indian innovation ecosystem to identify, nurture, and scale up innovative solutions in India and beyond. Our collaboration with GARDP will help especially in clinical development and validation of C-CAMP-supported AMR solutions, with the larger goal of driving sustainable and ethical access to emerging technologies. This access will be crucial to bending the growing curve of AMR in India and abroad."